Dr. Srujan Gandham
Associate Director, Analytical Development
at Aera Therapeutics
Srujan Gandham is the Associate Director of Analytical Development at Aera Therapeutics, where he leads analytical method development efforts focused on the characterization and quantitation of novel delivery systems (PNPs). Before joining Aera, Srujan was at Moderna, where he developed analytical methods for the characterization and impurity profiling of drug substances(mRNA) and drug product (LNP/mRNA). He played a key role in several of Moderna’s BLA and IND filings for various mRNA clinical programs, including mRNA-1273 (Moderna’s first COVID-19 vaccine). Srujan holds a PhD in Pharmaceutical Systems and Drug Delivery Systems from Northeastern University with research centered on understanding the contents of extracellular vesicles in mouse models of ovarian cancer.
Got a Question for Dr. Srujan Gandham?
Get in touch using the contact form linked here and we’ll get back to you shortly.